Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about IMRX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Atebimetinib | Pancreatic Cancer | Phase 3 · NCT07562152 | Recruiting |
| GnP | Pancreatic Cancer | Phase 3 · NCT07562152 | Recruiting |
| mGnP | Pancreatic Cancer | Phase 3 · NCT07562152 | Recruiting |
| MEK Inhibitor IMM-6-415 | Advanced Solid Tumor (Phase 1) | Phase 1/2 · NCT06208124 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
IMRX holds $166.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $16.6M/quarter from operations, an estimated runway of 29.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 15 · Low
Based on our current business plans, we believe that our existing cash, cash equivalents and marketable securities as of September 30, 2026 will enable us to fund our development activities and other operations into the fourth quarter of 2028.10-Q, Oct 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IMRX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| FMR, LLC | Institution (13F) | 9,193,275 | 35.44% | 2026-09-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 4,356,235 | 16.79% | 2026-06-30 |
| Benjamin J. Zeskind PRESIDENT AND CEO, Director · +688,000 options |
Insider | 3,210,179 | 12.38% | 2026-06-23 |
| Sanofi | Institution (13F) | 2,708,559 | 10.44% | 2026-09-30 |
| Vanguard Capital Management LLC | Institution (13F) | 2,284,882 | 8.81% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 1,374,279 | 5.30% | 2026-09-30 |
| Price (T.Rowe) Associates Inc | Institution (13F) | 1,235,304 | 4.76% | 2026-09-30 |
| Peter Feinberg Director · +41,238 options |
Insider | 1,161,064 | 4.48% | 2026-01-12 |
| State Street Corporation | Institution (13F) | 1,152,239 | 4.44% | 2026-09-30 |
| Nuveen, LLC | Institution (13F) | 869,390 | 3.35% | 2026-09-30 |
| DCF Advisers, LLC | Institution (13F) | 862,500 | 3.33% | 2026-09-30 |
| Aberdeen Group plc | Institution (13F) | 784,951 | 3.03% | 2026-09-30 |
Share count 25,938,064 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-13 filed 2026-11-16 |
Gengos Andrew |
Purchase (P) | 25,000 | $3.58 | 250,000 |
| 2026-11-09 filed 2026-11-09 |
Bogle Grant C. |
Option award (A) | 66,700 | – | – |
| 2026-07-16 filed 2026-07-17 |
Gengos Andrew |
Option award (A) | 650,000 | – | – |
| 2026-06-23 filed 2026-06-24 |
Zeskind Benjamin J. |
Purchase (P) | 2,400 | $4.56 | 2,315,252 |
| 2026-06-15 filed 2026-06-16 |
Hall Brett Matthew |
Purchase (P) | 6,035 | $4.15 | 382,531 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMRX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →